ABCELY

French tech company | Builders Republic

About

Biotech developing orally-active class A immunoglobulins (IgA) for the treatment of mucosal cancers — its lead candidate ABC101, an oral anti-CEA antibody, targets digestive, respiratory and urogenital tumours that overexpress the carcinoembryonic antigen marker.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Seed
Founded
2022
City
NANTES
Region
Pays de la Loire
Tracked rounds
1
Amount raised
2.4 M€ raised since 2020

Funding rounds

  • Seed — 2023

Investors